JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Strong Q3 Performance and Favorable Conditions Drive Buy Rating
- Adaptive Biotechnologies Reports Strong Q3 2025 Growth
- Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies reports Q3 EPS 6c, consensus (14c)
- AMD, PLTR, NFLX: Cathie Wood Loads Up on HOOD and Netflix, Sells Advanced Micro and Palantir Stocks